Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 9839685, 12 pages
http://dx.doi.org/10.1155/2016/9839685
Research Article

Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data

1Department of Medical Oncology, Barretos Cancer Hospital, Barretos, SP, Brazil
2Department of Oncology, Marcio Cunha Hospital, Fundação São Francisco Xavier, Ipatinga, MG, Brazil
3Post Graduation Program in Oncology, Barretos Cancer Hospital, Barretos, SP, Brazil
4Pathology, Clinicas Oncologicas Integradas, Rio de Janeiro, RJ, Brazil
5Barretos School of Health Sciences (FACISB), Barretos, SP, Brazil

Received 13 April 2016; Revised 20 July 2016; Accepted 18 August 2016

Academic Editor: Mario Clerici

Copyright © 2016 Gustavo Dix Junqueira Pinto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. Ministerio da Saúde, Estimativas 2016/2017 por Tipos de Câncer Rio de Janeiro, Instituto Nacional do Câncer, Rio de Janeiro, Brazil, 2015.
  3. R. J. Kelly, J. Gulley, and G. Giaccone, “Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality,” Clinical Lung Cancer, vol. 11, no. 4, pp. 228–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,” Nature Reviews Cancer, vol. 12, no. 4, pp. 252–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. H. Sharpe and G. J. Freeman, “The B7–CD28 superfamily,” Nature Reviews Immunology, vol. 2, no. 2, pp. 116–126, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Karachaliou, M. G. Cao, C. Teixidó et al., “Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints,” Cancer Biology and Medicine, vol. 12, no. 2, pp. 79–86, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo, “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,” EMBO Journal, vol. 11, no. 11, pp. 3887–3895, 1992. View at Google Scholar · View at Scopus
  8. T. Shinohara, M. Taniwaki, Y. Ishida, M. Kawaichi, and T. Honjo, “Structure and chromosomal localization of the human PD-1 gene (PDCD1),” Genomics, vol. 23, no. 3, pp. 704–706, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Blank, I. Brown, A. C. Peterson et al., “PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells,” Cancer Research, vol. 64, no. 3, pp. 1140–1145, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Blank and A. Mackensen, “Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion,” Cancer Immunology, Immunotherapy, vol. 56, no. 5, pp. 739–745, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. J. Butte, V. Peña-Cruz, M.-J. Kim, G. J. Freeman, and A. H. Sharpe, “Interaction of human PD-L1 and B7-1,” Molecular Immunology, vol. 45, no. 13, pp. 3567–3572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. G. J. Freeman, A. J. Long, Y. Iwai et al., “Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation,” The Journal of Experimental Medicine, vol. 192, no. 7, pp. 1027–1034, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Dong, G. Zhu, K. Tamada, and L. Chen, “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nature Medicine, vol. 5, no. 12, pp. 1365–1369, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Dong, S. E. Strome, D. R. Salomao et al., “Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion,” Nature Medicine, vol. 8, no. 8, pp. 793–800, 2002. View at Google Scholar
  15. S. L. Topalian, C. G. Drake, and D. M. Pardoll, “Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity,” Current Opinion in Immunology, vol. 24, no. 2, pp. 207–212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato, “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 19, pp. 12293–12297, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. M. W. L. Teng, S. F. Ngiow, A. Ribas, and M. J. Smyth, “Classifying cancers based on T-cell infiltration and PD-L1,” Cancer Research, vol. 75, no. 11, pp. 2139–2145, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Chen, J. Mei, L. Liu et al., “PD-L1 expression is associated with advanced non-small cell lung cancer,” Oncology Letters, vol. 12, no. 2, pp. 921–927, 2016. View at Publisher · View at Google Scholar
  19. K. Takada, T. Okamoto, F. Shoji et al., “Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma,” Journal of Thoracic Oncology, 2016. View at Publisher · View at Google Scholar
  20. Y. J. Cha, H. R. Kim, C. Y. Lee, B. C. Cho, and H. S. Shim, “Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status,” Lung Cancer, vol. 97, pp. 73–80, 2016. View at Publisher · View at Google Scholar
  21. A. Calles, X. Liao, L. M. Sholl et al., “Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer,” Journal of Thoracic Oncology, vol. 10, no. 12, pp. 1726–1735, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Shimoji, S. Shimizu, K. Sato et al., “Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1),” Lung Cancer, vol. 98, pp. 69–75, 2016. View at Publisher · View at Google Scholar
  23. P. Waterhouse, J. M. Penninger, E. Timms et al., “Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4,” Science, vol. 270, no. 5238, pp. 985–988, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. L. L. Carter, L. A. Fouser, J. Jussif et al., “PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2,” European Journal of Immunology, vol. 32, no. 3, pp. 634–643, 2002. View at Google Scholar · View at Scopus
  25. G. Toyokawa, K. Takada, N. Haratake et al., “Favorable disease-free survival associated with programmed death ligand 1 expression in patients with surgically resected small-cell lung cancer,” Anticancer Research, vol. 36, no. 8, pp. 4329–4336, 2016. View at Google Scholar
  26. S. E. Strome, H. Dong, H. Tamura et al., “B7–H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma,” Cancer Research, vol. 63, no. 19, pp. 6501–6505, 2003. View at Google Scholar · View at Scopus
  27. E. B. Garon, N. A. Rizvi, R. Hui et al., “Pembrolizumab for the treatment of non-small-cell lung cancer,” The New England Journal of Medicine, vol. 372, no. 21, pp. 2018–2028, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Passiglia, G. Bronte, V. Bazan et al., “PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis,” Oncotarget, vol. 7, no. 15, pp. 19738–19747, 2016. View at Publisher · View at Google Scholar
  29. E. M. G. Marcella Callea, M. Gupta, S. C. Cheng et al., “PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases,” Journal of Clinical Oncology, vol. 32, supplement 5, abstract 4585, 2014. View at Google Scholar
  30. A. M. Marti, P. Martinez, A. Navarro et al., “Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung,” Journal of Clinical Oncology, vol. 32, supplement 5, abstract 7569, 2014, Proceedings of the 2014 ASCO Annual Meeting. View at Google Scholar
  31. G. Schmid-Bindert and T. Jiang, “First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and ‘the sorcerers apprentice’,” Translational Lung Cancer Research, vol. 4, no. 3, pp. 215–216, 2015. View at Google Scholar
  32. A. D'Incecco, M. Andreozzi, V. Ludovini et al., “PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients,” British Journal of Cancer, vol. 112, no. 1, pp. 95–102, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Brahmer, K. L. Reckamp, P. Baas et al., “Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer,” The New England Journal of Medicine, vol. 373, no. 2, pp. 123–135, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. M.-Y. Kim, J. Koh, S. Kim, H. Go, Y. K. Jeon, and D. H. Chung, “Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers,” Lung Cancer, vol. 88, no. 1, pp. 24–33, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Velcheti, K. A. Schalper, D. E. Carvajal et al., “Programmed death ligand-1 expression in non-small cell lung cancer,” Laboratory Investigation, vol. 94, no. 1, pp. 107–116, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. K. M. Kerr, M.-S. Tsao, A. G. Nicholson, Y. Yatabe, I. I. Wistuba, and F. R. Hirsch, “Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?” Journal of Thoracic Oncology, vol. 10, no. 7, pp. 985–989, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. “Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538),” in Proceedings of the ASCO Annual Meeting, J. Grosso, C. E. Horak, D. Inzunza et al., Eds., 2013.
  38. Z. Gatalica, C. Snyder, T. Maney et al., “Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type,” Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 12, pp. 2965–2970, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura, “B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression,” Clinical Cancer Research, vol. 10, no. 15, pp. 5094–5100, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. “PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea,” in Proceedings of the ASCO Annual Meeting, J.-M. Sun, W. Zhou, Y.-L. Choi et al., Eds., 2014.
  41. R. S. Herbst, J.-C. Soria, M. Kowanetz et al., “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients,” Nature, vol. 515, no. 7528, pp. 563–567, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. M. J. Smyth, S. F. Ngiow, A. Ribas, and M. W. L. Teng, “Combination cancer immunotherapies tailored to the tumour microenvironment,” Nature Reviews Clinical Oncology, vol. 13, no. 3, pp. 143–158, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. S. P. Kerkar and N. P. Restifo, “Cellular constituents of immune escape within the tumor microenvironment,” Cancer Research, vol. 72, no. 13, pp. 3125–3130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. A. S. McDaniel, A. Alva, T. Zhan et al., “Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma,” European Urology Focus, vol. 1, no. 3, pp. 265–268, 2016. View at Publisher · View at Google Scholar
  45. K. Lin, J. Cheng, T. Yang, Y. Li, and B. Zhu, “EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB,” Biochemical and Biophysical Research Communications, vol. 463, no. 1-2, pp. 95–101, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Brambilla, Ed., The World Conference on Lung Cancer, PD1/PDL1 Biomarker Strategies, Denver, Colo, USA, 2015.
  47. H. S. Kim, J. Y. Lee, S. H. Lim et al., “Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma,” Cancer Research and Treatment, vol. 48, no. 2, pp. 527–536, 2016. View at Publisher · View at Google Scholar
  48. Z. J. Zhou, P. Zhan, and Y. Song, “PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis,” Translational Lung Cancer Research, vol. 4, no. 2, pp. 203–208, 2015. View at Google Scholar